Shantha Biotechnics Ltd Products and Operations

Shantha Biotechnics Ltd is a well-established biotechnology company that has been making waves in the industry. They are known for their innovative approach to healthcare.

Their product portfolio includes a range of vaccines and biologics that cater to various health needs.

One of their notable products is the Rotavirus vaccine, which has been instrumental in protecting children from this severe and often life-threatening disease. Shantha Biotechnics Ltd has been successfully manufacturing and distributing this vaccine in several countries.

Their operations are built on a strong foundation of research and development, ensuring that their products are of the highest quality and efficacy.

Check this out: Allcargo Gati Ltd

Shantha Biotechnics has developed a range of products, including SHANVAC-B, SHANFERON, SHANKINASE, SHANPOIETIN, pediatric combination vaccines Shantetra and Shan5, SHAN HIB-DPT, SHAN HIB, and SHANTT.

The company's products cater to various needs, from vaccines to medications.

One notable project undertaken by Shantha Biotechnics is the Insuman Cartridges Project, which aims to produce insulin at a lower cost in the Medak district of Telangana.

See what others are reading: Harbinger Knowledge Products

Shantha has developed a range of products, including SHANVAC-B and SHANFERON.

Their portfolio also includes SHANKINASE and SHANPOIETIN.

The company offers pediatric combination vaccines, such as Shantetra and Shan5.

SHAN HIB-DPT and SHAN HIB are also part of their product lineup.

These products showcase the company's capabilities in developing a variety of medications and vaccines.

The Insuman Cartridges Project is all about making insulin more affordable. It's located in Medak district, Telangana.

The project's main goal is to produce insulin at a lower cost. This is a significant step towards making healthcare more accessible to people in need.

The project's cost is a whopping ₹ 460 crore.

Shantha Biotechnics has been a leading manufacturer of vaccines in India for over three decades.

The company was founded in 1989 by three entrepreneurs, including G.V. Prasad, who is currently the chairman of the board.

Shantha Biotechnics has a strong presence in the global vaccine market, with a portfolio of vaccines that includes Hepatitis B, Hib, and Pentavalent.

The company's vaccines are used in over 100 countries worldwide.

Shantha Biotechnics has a strong commitment to social responsibility, with a focus on improving healthcare outcomes in underserved communities.

The company has partnered with various organizations to support vaccination programs and improve access to healthcare services.

Shantha Biotechnics has a state-of-the-art manufacturing facility in Hyderabad, India, that adheres to global quality standards.

The company has received numerous awards and recognition for its contributions to public health and vaccine manufacturing.

Worth a look: Sanofi Aventis Healthcare

Shantha Biotechnics has received a significant nod from the World Health Organization (WHO). They've been granted approval for their cholera vaccine, which is a major breakthrough in the field of public health.

This vaccine is the first cholera vaccine to receive approval for storage and distribution outside of the traditional cold chain. This means that it can be transported and stored in a wider range of environments, making it more accessible to people in need.

The WHO's approval is a testament to Shantha Biotechnics' commitment to developing high-quality vaccines. Their cholera vaccine has been recognized as a "mass campaign" vaccine, indicating its potential for widespread use in public health initiatives.

This approval is a significant milestone for Shantha Biotechnics, and it's likely to have a positive impact on global health efforts.

Shantha Biotechnics has established a strong presence in the vaccine market, with a diverse portfolio of products that cater to various diseases.

The company's operations are spread across multiple locations, including a manufacturing facility in Bengaluru, Karnataka, and a research and development center in Hyderabad, Telangana.

Shantha Biotechnics has been able to expand its reach through strategic partnerships and collaborations with other companies.

Shantha Biotechnics, Ltd. was founded in 1993 by Dr. K. I. Varaprasad Reddy and Khalil Ahmed with the goal of producing affordable drugs while maintaining international quality standards.

The company's journey began as an R&D project at Osmania University in 1993, and later operated from the Center for Cellular and Molecular Biology until its own research facility was built.

In 2006, Mérieux Alliance acquired a 60% stake in Shantha Biotechnics for $175 million, marking a significant milestone in the company's growth.

This acquisition was followed by another major deal in 2009, when Sanofi Pasteur acquired the stake held by Mérieux Alliance for Euro 550 million, valuing Shantha Biotech at over Rs 3,770 crore.

By 2013, Sanofi had acquired 100% of Shantha Biotechnics, solidifying its position as a major player in the industry.

On a similar theme: Alternative Distribution Alliance

We're excited to announce that our company has started commercial production at its new unit. This move marks a significant milestone in our operations and expansion efforts.

The new unit has been designed to increase our production capacity by 30%. This will enable us to meet the growing demand for our products and services.

Our team has worked tirelessly to ensure a smooth transition to the new unit. They've successfully transferred all equipment and personnel, and production is now up and running.

The new unit will also enable us to reduce our production costs by 25%. This will help us to maintain our competitive edge in the market.

We're proud of what we've achieved so far, and we're looking forward to continuing to grow and expand our operations.

Intriguing read: Concord New Energy

Shantha Biotech has received funding through a single round, a Grant (prize money) round on September 25, 2007, for an undisclosed amount.

This funding round involved just one investor, the Department of Biotechnology.

Shantha Biotech has had the support of the Department of Biotechnology in its latest funding round.

Broaden your view: Unity Biotechnology

Shantha Biotechnics Ltd was founded in 1993 with a mission to produce cost-effective vaccines for the common man.

The company's first major achievement was developing India's first indigenously developed recombinant hepatitis B vaccine.

Shantha Biotechnics Ltd successfully launched the Shanvac-B vaccine in 1997, marking a significant milestone in the country's vaccine development.

The company's commitment to international quality standards is evident in its development of the Shanvac-B vaccine.

You might enjoy: Hungarian Development Bank